Array stock: buy or sell?

ARRY stock price: $47.85 0.00% At close on July 30th, 2019

Updated on:
July 30th, 2019


After reaching all time highs on July/30, Array stayed steady 0.00% to $47.85. July/30 was the 3rd climbing day in a row, gaining 1.98%.

Array BioPharma Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule drugs to treat patients with cancer in North America, Europe, and the Asia Pacific.

Should I buy Array stock?

Even if you are a experienced or a novel trader, best trading results come from using an investing strategy that never leaves to random or subjective opinions when is the best moment to buy or sell stocks. That's why is so important to define your own trading plan that matches with your character as inversor. There are thousands of trading strategies for you to choose, but at we prefer those that are simple but successful.

Currently, 2 buy setups are elegible for Array stock right now:

Buy setupElegible
New all-time highYes
New 52 week highYes
Price crossing up 200d MANo
100d MA crossing up 200d MANo

Is Array BioPharma stock a buy?

Everyday, hundreds of stock ratings are posted by financial analysts to indicate a particular stock's attractiveness. At, we collected 15 ratings published for ARRY stock in the last 30 days.

Is ARRY a good stock to buy?
DateAnalyst / BrokerPrevious ratingCurrent rating
2019-7-8Cantor FitzgeraldOverweightNeutral
2019-7-12JPMorgan Chase & Co.OverweightNeutral
2019-6-18Svb LeerinkOutperformMarket Perform
2019-6-18Leerink SwannOutperformMarket Perform
2019-6-18Goldman Sachs Groupn/aNeutral
2019-6-17Wells Fargo & CoOutperformMarket Perform
2019-6-17SunTrust BanksBuyHold
2019-6-17Piper Jaffray CompaniesOverweightNeutral
2019-6-17Jefferies Financial GroupBuyHold
2019-5-22SunTrust Banksn/aBuy
2019-5-21Piper Jaffray Companiesn/aOverweight
2019-3-14JPMorgan Chase & Co.PositiveOverweight
2019-1-17Leerink Swannn/aOutperform
2019-1-15Piper Jaffray CompaniesOverweightPositive

Array stock analysis

Daily outlook

Array shares peaked new all time highs back again on Jul/30, setting highs to $47.98. Shares closed at $47.85 and stayed stable 0.00%.

After climbing to all-time highs several times in past weeks, Array BioPharma stayed stable 0.00% to $47.85. ARRY broke out again over $47.01 after a 1.68% correction started on July. On May ARRY price bounced up over the SMA of 100 days demonstrating to be a significant support for this stock.

ARRY stock chart (daily)

Weekly outlook

Shares of Array ended this week at $47.85 after marking a new all time high ($47.98) and gained a slightly good 1.18%. By mid June ARRY rocketed an extraordinary 35.95% in just one week.

Price pattern shows an uptrend with two rising tops and bottoms, and now finally trading above the $47.05 resistance. Early February, SMA20w and SMA40w crossed up triggering a rise of 149.22%. Late December 2018 ARRY price bounced up over the SMA of 40 weeks that acted as support stopping new slides.

ARRY stock chart (weekly)

Array stock price history

Array IPO was on November 30th, 2000 at $8.75 per share1. Since then, ARRY stock grew a 446.90%, with an average of 24.80% per year. If you had invested $1,000 in Array stock in 2000, it would worth $4,469.00 today.

1: Adjusted price after possible price splits or reverse-splits.

Array stock historical price chart

ARRY stock reached all-time highs on Jul/30 with a price of $47.98.

Array stock price target is $36.80

How much a stock will be priced tomorrow or next week is quite unpredictable However, financial institutions invest time and resources to provide the most accurated estimations to help investors to make their decisions. You should not follow the analysts' ARRY stock price predictions in the hope that they will be met as they may be wrong and not met. We found 9 price forecasts for Array stock published in the last month:
ARRY stock price predictions
DateAnalyst / BrokerActionPrevious targetCurrent targetDiff
2019-7-8Cantor FitzgeraldDowngrades$34.00$48.0041.2%
2019-7-12JPMorgan Chase & Co.Downgrades$29.00$48.0065.5%
2019-6-18Svb LeerinkReiterates$32.00$48.0050%
2019-6-18Goldman Sachs GroupRaises Target$27.00$38.0040.7%
2019-5-22SunTrust BanksRaises Targetn/a$32.00-
2019-5-21Piper Jaffray CompaniesReiterates$28.00$35.0025%
2019-3-14JPMorgan Chase & Co.Reiterates$18.00$29.0061.1%
2019-1-15Piper Jaffray CompaniesReiteratesn/a$28.00-
(in average)$28.00$36.8031.0%
The price target for Array stock is $36.80, moving in a range between $48.00 and $25.00. In average, analysts' outlook on ARRY price forecast is positive, improving the prediction by a 31.00% from previous estimations.

Financials and fundamental analysis

Earnings date and Earnings per Share

On February, Array BioPharma missed the estimates of the experts and posted a bloodcurdling EPS of $-0.05 per share when experts were expecting $-0.16.
ARRY earnings date and EPS evolution
QuarterReporting dateEstimated EPSActual EPSSurprise

Annual financial results

In 2018, Array BioPharma annual revenues rocketed an extraordinary 15.19% to $173.77 M USD from $150.85 marked in 2017. When comparing 2018 vs 2017, however, profit margin (that is, the net income divided by revenues) slipped a -7.36% to -84.79%.

To have an up to date picture of the financial situation of Array, we have calculated the trailing twelve month (TTM) sales and income figures. TTM values are the sum of the last 4 quarters and aproximate to an annual fiscal report ending in 2018-Q4 that can be compared to 2018 fiscal year results. Annual Array TTM sales up to December 2018 were $241.26 and earnings were $-111.47 million USD. When comparing this TTM figures with the last reported annuality, we can review Array business evolution since June 2018: Annual turnover up to December, compared to lastest yearly report, boosted a dazzling 38.84%. Regarding profit margin, Array climbed 38.59% to -84.79%

ARRY annual Sales and Income evolution
2013$70 M-$-61.94 M-89.0%-
2014$42 M-39.52%$-85.26 M-202.6%37.65%
2015$52 M23.36%$9.37 M18.0%-110.99%
2016$138 M165.62%$-92.84 M-67.3%-1,090.93%
2017$151 M9.41%$-116.82 M-77.4%25.83%
2018$174 M15.19%$-147.35 M-84.8%26.13%
TTM $241 M38.84%$-111.47 M-46.2%-24.35%

Quarterly financial results

Array reported $82.55 million in revenues for 2018-Q4, a 45.05% up compared to previous quarter. Reported quarter earnings marked $-11.36 M with a profit margin of -13.76%. Profit margin boosted a 29.83% compared to previous quarter when profit margin was -43.60%. When comparing turnover to same quarter last year, Array BioPharma sales marked a super good growth and climbed a 95.53%. Looking back to recent quarterly results, Array posted 2 positive quarters in a row.
ARRY quarterly Sales and Income evolution
2017-Q1$33 M-$-35.32 M-106.1%-
2017-Q2$34 M1.50%$-29.59 M-87.6%-16.22%
2017-Q3$30 M-11.94%$-37.99 M-127.7%28.40%
2017-Q4$42 M41.93%$-34.05 M-80.7%-10.37%
2018-Q1$66 M57.20%$-22.85 M-34.4%-32.90%
2018-Q2$35 M-46.60%$-52.45 M-148.0%129.52%
2018-Q3$57 M60.59%$-24.81 M-43.6%-52.69%
2018-Q4$83 M45.05%$-11.36 M-13.8%-54.21%

Array ownership

When you are planning to buy a stock, it's worth to have a look its ownership structure.

Array shares owned by insiders (that is, founders, CEO, CTO, main executives or other management staff) currently counts a 0.38% of all shares.

Bearish positions for ARRY stock account 0.00%, no big difference from last month.

The following table compares ownership indicators for other stocks related to Array:

Market cap$10.6 B
Total shares221.8 M
Float shares220.9 M
  - Institutional holdings (%)100.7%
  - Insider holdings (%)0.4%
Shares in short selling0.0%

Array summary

Tuesday, July 30th, 2019
Day range$47.84 - $47.98
Previous close$47.85
Session gain0.00%
Average true range$0.38
50d mov avg$39.37
100d mov avg$31.28
200d mov avg$24.31
Daily patternlb01c
Weekly pattern lb02c

Array performance

Stocks performance is always measured in comparision to the market or competitors and related stocks in the same industry. We selected as the bechmarking frame for Array stock.
ARRYArray BioPharma106.52%149.22%216.47%

Array competitors

Unfortunately, we could not find any public company that could be defined as Array competitor. This doesn't mean Array does not have any competitor in the market, it's just we could not detected it.